Clinical Trial Detail

NCT ID NCT03891979
Title Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma
Recruitment Withdrawn
Gender both
Phase FDA approved
Variant Requirements No
Sponsors New York University School of Medicine
Indications

pancreatic adenocarcinoma

Therapies

Ciprofloxacin

Metronidazole

Pembrolizumab

Age Groups: senior adult child

No variant requirements are available.